1. Home
  2. CANF vs BLMZ Comparison

CANF vs BLMZ Comparison

Compare CANF & BLMZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CANF
  • BLMZ
  • Stock Information
  • Founded
  • CANF 1994
  • BLMZ 2017
  • Country
  • CANF Israel
  • BLMZ Japan
  • Employees
  • CANF N/A
  • BLMZ N/A
  • Industry
  • CANF Biotechnology: Pharmaceutical Preparations
  • BLMZ
  • Sector
  • CANF Health Care
  • BLMZ
  • Exchange
  • CANF Nasdaq
  • BLMZ NYSE
  • Market Cap
  • CANF 14.4M
  • BLMZ 15.5M
  • IPO Year
  • CANF N/A
  • BLMZ 2024
  • Fundamental
  • Price
  • CANF $2.51
  • BLMZ $1.31
  • Analyst Decision
  • CANF Strong Buy
  • BLMZ
  • Analyst Count
  • CANF 2
  • BLMZ 0
  • Target Price
  • CANF $14.00
  • BLMZ N/A
  • AVG Volume (30 Days)
  • CANF 135.4K
  • BLMZ 5.1M
  • Earning Date
  • CANF 11-15-2024
  • BLMZ 11-15-2024
  • Dividend Yield
  • CANF N/A
  • BLMZ N/A
  • EPS Growth
  • CANF N/A
  • BLMZ N/A
  • EPS
  • CANF N/A
  • BLMZ N/A
  • Revenue
  • CANF $667,000.00
  • BLMZ $1,246,643.00
  • Revenue This Year
  • CANF $356.93
  • BLMZ N/A
  • Revenue Next Year
  • CANF N/A
  • BLMZ N/A
  • P/E Ratio
  • CANF N/A
  • BLMZ N/A
  • Revenue Growth
  • CANF N/A
  • BLMZ 29.63
  • 52 Week Low
  • CANF $1.81
  • BLMZ $0.68
  • 52 Week High
  • CANF $4.69
  • BLMZ $4.30
  • Technical
  • Relative Strength Index (RSI)
  • CANF 64.60
  • BLMZ N/A
  • Support Level
  • CANF $1.87
  • BLMZ N/A
  • Resistance Level
  • CANF $2.55
  • BLMZ N/A
  • Average True Range (ATR)
  • CANF 0.17
  • BLMZ 0.00
  • MACD
  • CANF 0.08
  • BLMZ 0.00
  • Stochastic Oscillator
  • CANF 93.75
  • BLMZ 0.00

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

About BLMZ BLOOMZ INC

BloomZ Inc operates as an audio-producing and voice actor managing company. The company provides audio production services and voice-acting educational services in Japan. The business lines of the company are the audio production business, the VTuber management business, and the voice actor workshop business. The audio production comprises producing audios for animations and video games using dubbing, BGM producing, and mixing techniques; the Vtuber management business creates motion-capture technology for streamers to provide the voice to stream real-time videos featuring human facial expressions and gestures; and the voice actor workshop provides practical voice acting services.

Share on Social Networks: